Malignant is a somewhat atypical book in the cancer space, as Prasad admits in his introduction. It reads a lot more like a combination of investigative journalism and outraged policy wonk (perhaps The Weeds podcast would like him on?) than my preconception of the 'typical' cancer book, which, according to
Would one way to tackle some of this would be to enforce follow up survival trials or other proper confirmatory trials, in a reasonable timeframe and to enforce delisting of a drug if it fails. I was interested to read your take on the reputational capital concerns of the FDA and would be interested in your views on the latest Alzheimer’s approval.
Would one way to tackle some of this would be to enforce follow up survival trials or other proper confirmatory trials, in a reasonable timeframe and to enforce delisting of a drug if it fails. I was interested to read your take on the reputational capital concerns of the FDA and would be interested in your views on the latest Alzheimer’s approval.